Senior Consultant for Gerontology, Guinness World Records, Gerontology Research Group, Sandy Springs, Georgia.
GRG Supercentenarian Research and Database Division, Gerontology Research Group, Sandy Springs, Georgia.
Rejuvenation Res. 2020 Feb;23(1):48-64. doi: 10.1089/rej.2020.2303.
This article discusses the need for biosampling as a way to test "super-duper" centenarians (persons aged >120 years) to identify biological pathways for to live to their fullest biological lifespan potential (estimated by extreme value theory to be currently between 123 years and 128 years) and, by extension, the possibility of biosampling leading to the identification through scientific research testing and data analysis areas of potential life extension. Studies of twins have shown that the proportion of longevity attributed to heredity (genetic potential) versus environment increases substantially the higher the age group being tested, especially after age 75 years. Even among the oldest-old, the proportion attributed to biological factors continues increasing the higher the age category, which is a selective process as the genetically weaker of the remaining survivors continue to die off first, leaving a more and more highly selected remaining population. This self-selection process means that the very oldest individuals are already the "genetic lottery winners" who have the biological potential to come close to the maximum human lifespan. Testing of these persons may result in faster breakthroughs in the attempt to extend the human lifespan through biological testing and analysis. Indeed, it is possible that, just as some human lifespans are shortened due to random genetic mutations unique to the individual (such as persons with progeria), it is possible that there could be some humans whose maximum genetic potential was due in part to a genetic mutation unique to that particular individual. This remains an area of potential research that has not yet been thoroughly biotested-but one that could change soon, and biotesting a 122-year-old woman's biosamples would be a prime opportunity for such a test: Jeanne Calment. Because only one 122-year-old woman has been validated in recorded scientific history, the uniqueness of the case makes it a unique opportunity that should not be passed by. Herewith, I take a closer look at the Jeanne Calment case and the conclusion is the same as the start: Jeanne Calment was 122 years, her age is relatively unique but not impossible to repeat in the future; however, her samples may be available right now, and thus remains the only current opportunity to study a >120-year-old person from a biological perspective.
本文讨论了进行生物样本采样的必要性,以便对“超级百岁老人”(年龄>120 岁的人)进行测试,以确定他们达到最大生物学寿命潜力的生物学途径(根据极值理论估计,目前在 123 岁至 128 岁之间),并由此延伸到生物样本采样可能导致通过科学研究测试和数据分析来确定潜在的寿命延长领域。对双胞胎的研究表明,长寿归因于遗传(遗传潜力)与环境的比例随着被测试的年龄组的增加而大幅增加,尤其是在 75 岁以后。即使在最年长的人群中,归因于生物学因素的比例随着年龄组的增加而继续增加,这是一个选择性过程,因为较弱的遗传幸存者首先继续死亡,留下越来越多的高度选择的剩余人群。这种自我选择过程意味着,最年长的个体已经是“遗传彩票赢家”,他们具有接近人类最大寿命的生物学潜力。对这些人的测试可能会导致通过生物测试和分析来延长人类寿命的突破更快。事实上,有可能,就像有些人的寿命由于个体特有的随机遗传突变而缩短一样(例如患有早衰症的人),也有可能有些人的最大遗传潜力部分归因于该特定个体特有的遗传突变。这仍然是一个潜在的研究领域,尚未经过全面的生物测试——但这一领域可能很快就会发生变化,对 122 岁女性的生物样本进行生物测试将是一个绝佳的机会:珍妮·卡尔芒。由于在有记录的科学历史中只有一位 122 岁的女性得到了验证,因此这个案例的独特性使得这是一个不容错过的独特机会。在此,我更仔细地研究了珍妮·卡尔芒的案例,结论与开始时相同:珍妮·卡尔芒 122 岁,她的年龄相对独特,但并非不可能在未来重复;然而,她的样本现在可能可用,因此仍然是从生物学角度研究 120 岁以上人群的唯一当前机会。